Stephen Hoge reported a Moderna share sale on Form 4

What did Stephen Hoge report?

The SEC Form 4 reports an open-market sale by Stephen Hoge, President and Officer, of 39,145 Moderna (MRNA) shares at $220.72 each. The reported value is about $8.64M.

The transaction date was Oct 15, 2026. The filing date was Oct 16, 2026, 1 day later. The same person’s filings also report an exercise or conversion of derivative securities, transaction code M or C, dated Oct 15, 2026: Officer exercised or converted 76K MRNA derivative securities.

How does the sale fit the filing history?

The trade was made 76 days after Moderna’s results announcement of Jul 31, 2026, reported under 8-K Item 2.02. In the 455 days to Oct 16, 2026, OQRO holds 16 open-market sales by Moderna insiders, counted once per person and day; 6 were made within 30 days after a results announcement.

In the 365 days to Oct 16, 2026, OQRO holds 8 other open-market sales by Stephen Hoge, about $36.8M in total, with 8 at Moderna. At Moderna, 11 other open-market sales by 4 insiders were filed in the 90 days to Oct 16, 2026, for about $54M. In the 365 days before that, 10 were filed, about $19.1M, an average of 2.5 per 90 days.

The largest other filings of the same kind in that period were by Stephane Bancel, Chief Executive Officer: about $11M, filed Aug 7, 2026 and about $8.29M, filed Aug 7, 2026.

What other Moderna filings are on record?

Members of Congress filed 3 other disclosures on Moderna in the 90 days to Oct 16, 2026: 1 purchase and 2 sales, by 1 member. The largest range among them was Rep. Maria Elvira Salazar (FL27), $1,001 to $15,000, in a disclosure filed Oct 7, 2026.

Schedule 13D and 13G filings in the 180 days to Oct 16, 2026 show Capital World Investors owning 5.6% of MRNA as a passive investor, filed Aug 12, 2026, and BAILLIE GIFFORD & CO cutting its MRNA stake below 5% to 4.6%, filed Jul 24, 2026. Fund 13F filings in the 90 days to Oct 16, 2026 show 0 new or larger positions and 4 smaller or closed positions in Moderna.

For the quarter ended Jun 30, 2026, the largest growing positions in 13F filings included Capital World Investors, increased by 3,579,302 shares, and BAMCO Inc, a new position. The largest shrinking positions included Jacobs Levy Equity Management, Inc and Voloridge Investment Management, LLC, both sold out. FINRA short interest for MRNA on Sep 30, 2026 was 30,863,202 shares, -6.11% on the previous report, about 1.83 days of average volume.

What else was happening around the trade date?

Moderna filed a Form 8-K on Sep 30, 2026, 15 days before the transaction, covering Items 5.02 and 7.01. OQRO classes it as a report of a changed top executive or board member and information shared with investors. The company’s opening sentence said Moderna announced the appointment of Juan Andres as Chief Operating Officer, effective October 5, 2026.

MRNA closed at $236.50 on Oct 15, 2026, the last session on or before the trade date. From Sep 15, 2026 to Oct 15, 2026, the close moved from $143.77 to $236.50, a change of +64.5%. Finnhub listed these Yahoo headlines on Oct 16, 2026: “Moderna Stock Slumps, but It’s Too Early to Panic”, “Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know”, and “Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather”.

What this does not tell you?

A Form 4 reports a transaction; it does not say why it was made. Some purchases and sales follow trading windows or pre-arranged plans, and OQRO notes a plan only when a filing footnote says so. This filing’s footnote mentions a planned or automatic transaction, but the Form 4 does not say which circumstances apply here. In general, a sale can also follow an option exercise or a tax bill.

An 8-K reports what the company said, not what it means for the share price. Headlines are listed as published by the outlets; OQRO has not checked them or summarized the articles. Price moves are context only, are not explained by the filing, and other news can move a price. A 13F is a quarter-end snapshot with no trade date.

Moderna’s proxy statement for fiscal 2025 reported total compensation of $19.9M for its principal executive officer and an average of $9.77M for the other named executive officers. Total compensation in a proxy statement counts stock and option awards at grant-date value, not what was sold. Comparisons use only filings OQRO holds. This describes public filings and is not investment advice.